GCP
JANX icon

GSA Capital Partners’s Janux Therapeutics JANX Stock Holding History

GSA Capital Partners’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$739K Sell
48,139
-2,212
-4% -$32K 0.05% 721
2026
Q1 		$700K Buy
+50,351
New +$690K 0.04% 706
2025
Q4 		– Sell
-15,463
Closed -$378K – 1882
2025
Q3 		$378K Buy
+15,463
New +$377K 0.03% 1052

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

GSA Capital Partners's JANX Position: Q2 2026 in Review

GSA Capital Partners reduced its Janux Therapeutics (JANX) stake by 4.4% in Q2 2026, selling an estimated $32K and leaving 48,139 shares worth $739K. The position accounts for 0.05% of the portfolio, ranked #721.

GSA Capital Partners first reported a position in JANX in Q3 2025 and has held it in 3 quarters since. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • GSA Capital Partners held 48,139 shares of Janux Therapeutics worth $739K as of Q2 2026.
  • GSA Capital Partners sold 2,212 Janux Therapeutics shares in Q2 2026, an estimated $32K.
  • Janux Therapeutics made up 0.05% of GSA Capital Partners's portfolio in Q2 2026, its #721 holding.
  • GSA Capital Partners first reported a position in Janux Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.